CROSSROADS OF CARE: Facing the Challenges of Heart Failure and Diabetes
April 01, 2019
In this symposium, Dr. James Januzzi and Dr. Mikhail Kosiborod will explain the intertwined relationship between diabetes and HF, and interpret safety and effi cacy data, focusing on HF-related outcomes, from studies with diabetes therapies.
CME 1.00 Credits
Hyperkalemia and Heart Failure: Recognizing Risks and Exploring Strategies for Improving Outcomes
February 24, 2019
In this program, Dr. Paul Hauptman and Dr. Javed Butler will 1) describe the relationship between RAAS inhibitors, hyperkalemia, and cardiovascular risk, 2) identify goals and treatments for acute, intermediate, and chronic management, and 3) discuss the clinical profi les of, and clinical settings for the use of, new potassium binders.
CME 1.00 Credits
LDL-Cholesterol Lowering and Atherosclerotic Cardiovascular Disease Risk Reduction: Exploring the Evidence With Non-Statin Therapy
June 17, 2018
n this program, lipid experts will present, in state-of-the-art lectures and in 'realworld' interactive cases, optimal strategies and provide 'take-home' messages for reducing risk in patients with elevated LDL-C.
No Credit Available
Heart Failure Management: Exploring Best Practices for the Internist
September 26, 2017
Experts Dr. Javed Butler and Dr. James Januzzi provide helpful insights on the topic of Heart Failure and offer best practices on heart failure management.
No Credit Available
LDL Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: EMERGING INSIGHTS
April 08, 2017
In this program, Dr. Lynn Braun and Dr. Michael Miller present lectures and case studies addressing the management of atherosclerotic cardiovascular disease along with best practices and treatment options.
No Credit Available
The Perfect Storm of Heart Failure and Diabetes: Insights into Pathophysiology and Evidence-Based Treatment Strategies
November 08, 2016
In this educational initiative, experts will address the needs of cardiologists for 1) a grasp of the relationship between DM and HF and the pathophysiology of HF in DM, 2) an explanation of clinical evidence for HF drugs in patients with DM, and 3) an assessment of the profiles of traditional and newer antidiabetic agents in patients with/at risk for cardiovascular disease and interpretation of heart failure-related outcomes.
No Credit Available